{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-075189","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.472625+00:00","generated_at":"2026-05-17T17:37:16.066434+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Natera Q2 revenue up 32% to $546.6M; raises FY2025 revenue outlook by $80M","bullets":["Total revenue $546.6M (+32.2% YoY); product revenue $544.4M (+32.3%).","Oncology tests grew 50.6% to 188,800; total tests processed 853,100 (+12.2%).","Achieved positive cash flow of ~$24.3M in Q2; cash and investments $1,016M.","Net loss per diluted share ($0.74) vs ($0.30) in Q2 2024, impacted by $19.8M legal accruals.","Raising 2025 revenue guidance to $2.02B-$2.10B from $1.94B-$2.02B; OpEx outlook unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-075189","json":"https://secwatch.observer/filing/0001104659-25-075189.json","markdown":"https://secwatch.observer/filing/0001104659-25-075189.md","text":"https://secwatch.observer/filing/0001104659-25-075189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925075189/0001104659-25-075189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925075189/tm2522162d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:37:16.066434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}